Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Devine

Showing results (31-40 of 178) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphomaSteven M Devine, Neal Flomenberg, David H Vesole, et al.
Infection Control and Hospital Epidemiology|February 1, 2007
Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading systemErik R Dubberke, Justin Sadhu, Robert Gatti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donorBeth Christian, Weiqiang Zhao, Mehdi Hamadani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2008
Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphomaTanya M Wildes, Kristan M Augustin, Diane Sempek, et al.
Blood|August 17, 2006
Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100Rebecca M Shepherd, Benjamin J Capoccia, Steven M Devine, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2024
Optimal Donor Selection Across Multiple Outcomes For Hematopoietic Stem Cell Transplantation By Bayesian Nonparametric Machine LearningRodney A Sparapani, Martin Maiers, Stephen R Spellman, et al.
Transplantation and Cellular Therapy|April 8, 2021
Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor ProductsJeffery J Auletta, Jen L Novakovich, Gretta L Stritesky, et al.
Journal of Clinical Apheresis|December 1, 2023
Validation of Nivestym compared to Neupogen: An NMDP analysisJoseph Maakaron, Katie Picotte, Kevin Tram, et al.
Plos One|July 23, 2011
CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cellsKechang Liu, Bryan A Anthony, Martha M Yearsly, et al.
International Journal of Bone Marrow Research|June 3, 2021
Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD)Yvonne A Efebera, Amy S Ruppert, Apollinaire Ngankeu, et al.
Pageof 18

Showing results (31-40 of 178) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphomaSteven M Devine, Neal Flomenberg, David H Vesole, et al.
Infection Control and Hospital Epidemiology|February 1, 2007
Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading systemErik R Dubberke, Justin Sadhu, Robert Gatti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donorBeth Christian, Weiqiang Zhao, Mehdi Hamadani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2008
Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphomaTanya M Wildes, Kristan M Augustin, Diane Sempek, et al.
Blood|August 17, 2006
Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100Rebecca M Shepherd, Benjamin J Capoccia, Steven M Devine, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2024
Optimal Donor Selection Across Multiple Outcomes For Hematopoietic Stem Cell Transplantation By Bayesian Nonparametric Machine LearningRodney A Sparapani, Martin Maiers, Stephen R Spellman, et al.
Transplantation and Cellular Therapy|April 8, 2021
Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor ProductsJeffery J Auletta, Jen L Novakovich, Gretta L Stritesky, et al.
Journal of Clinical Apheresis|December 1, 2023
Validation of Nivestym compared to Neupogen: An NMDP analysisJoseph Maakaron, Katie Picotte, Kevin Tram, et al.
Plos One|July 23, 2011
CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cellsKechang Liu, Bryan A Anthony, Martha M Yearsly, et al.
International Journal of Bone Marrow Research|June 3, 2021
Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD)Yvonne A Efebera, Amy S Ruppert, Apollinaire Ngankeu, et al.
Pageof 18